ArticleWorld journal of gastroenterology2018
Clinical impact of microbiome in patients with decompensated cirrhosis.
Article in World journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 34 citations in OpenAlex.
- Effects ofWorld journal of gastroenterology · 2024Trial
- Alterations in the Gut Microbiota of Cirrhotic Patients With Sarcopenia and PH After TIPS.Clinical and translational gastroenterology · 2026Article
- A prospective cohort-based prediction model incorporating acute gastrointestinal injury for 28-day and 90-day outcomes in acute decompensation of cirrhosis.BMC gastroenterology · 2026Observational
- Management of Refractory Hepatic Encephalopathy.Digestive diseases and sciences · 2026Review
- Gut Dysbiosis, Malnutrition and Sarcopenia in Liver Cirrhosis: A Narrative Review.Diseases (Basel, Switzerland) · 2026Review
- Mechanisms underlying the role of the oral-gut-liver axis in the promotion of liver fibrosis by periodontal disease: an interacting network of inflammation, microbiota, and barrier function.Frontiers in cellular and infection microbiology · 2026Review
- Gut microbiome and its metabolites in liver cirrhosis: mechanisms and clinical implications.Frontiers in cellular and infection microbiology · 2025Review
- Infections in decompensated cirrhosis: Pathophysiology, management, and research agenda.Hepatology communications · 2024Review
- Changes of the bacterial composition in duodenal fluid from patients with liver cirrhosis and molecular bacterascites.Scientific reports · 2023Article
- Review
- Modulation of duodenal and jejunal microbiota by rifaximin in mice with CClGut pathogens · 2023Article
- Investigation and characterization of human gut phageome in advanced liver cirrhosis of defined etiologies.Gut pathogens · 2022Article
- Relationship between Intestinal Microflora and Hepatocellular Cancer Based on Gut-Liver Axis Theory.Contrast media & molecular imaging · 2022Review
- Oral and Gut Microbial Dysbiosis and Non-alcoholic Fatty Liver Disease: The Central Role ofFrontiers in medicine · 2022Review
- Circadian Rhythms Coordinated With Gut Microbiota Partially Account for Individual Differences in Hepatitis B-Related Cirrhosis.Frontiers in cellular and infection microbiology · 2022Review
- Potential Gut Microbiota Features for Non-Invasive Detection of Schistosomiasis.Frontiers in immunology · 2022Article
- Role of Microbiota-Derived Metabolites in Alcoholic and Non-Alcoholic Fatty Liver Diseases.International journal of molecular sciences · 2021Review
- Gut microbiota signatures in Schistosoma japonicum infection-induced liver cirrhosis patients: a case-control study.Infectious diseases of poverty · 2021Article
- Gut microbiota mediated molecular events and therapy in liver diseases.World journal of gastroenterology · 2020Review
- Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders.Gastroenterology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cirrhosis is an increasing cause of morbidity and mortality. Recent studies are trying to clarify the role of microbiome in clinical exacerbation of patients with decompensated cirrhosis. Nowadays, it is accepted that patients with cirrhosis have altered salivary and enteric microbiome, characterized by the presence of dysbiosis. This altered microbiome along with small bowel bacterial overgrowth, through translocation across the gut, is associated with the development of decompensating complications. Studies have analyzed the correlation of certain bacterial families with the development of hepatic encephalopathy in cirrhotics. In general, stool and saliva dysbiosis with reduction of autochthonous bacteria in patients with cirrhosis incites changes in bacterial defenses and higher risk for bacterial infections, such as spontaneous bacterial peritonitis, and sepsis. Gut microbiome has even been associated with oncogenic pathways and under circumstances might promote the development of hepatocarcinogenesis. Lately, the existence of the oral-gut-liver axis has been related with the development of decompensating events. This link between the liver and the oral cavity could be
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.